Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Peritoneal Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Carcinoma, Renal Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma 1

Interventions

pembrolizumab 51 Ipilimumab 50 Cyclophosphamide 43 Nivolumab 41 aldesleukin 30 Interleukin-2 23 Vemurafenib 20 fludarabine 19 Temozolomide 18 fludarabine phosphate 15 dabrafenib 15 trametinib 12 spartalizumab 10 Radiotherapy 10 Radiosurgery 10 Dacarbazine 10 CTLA-4 Antigen 10 cobimetinib 9 binimetinib 9 poly ICLC 7 encorafenib 7 Paclitaxel 7 atezolizumab 6 Introns 6 Biopsy 6 montanide ISA 51 5 Carboplatin 5 epacadostat 4 MART-1 Antigen 4 Interferon alpha-2 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Melanoma × volociximab × Clear all

NCT00369395 2012-04-27

A Study of Volociximab in Metastatic Melanoma

Abbott

Phase 2 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡